Current issues in the management of advanced Hodgkin's disease

G. Bonadonna, A. Santoro

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

During the past two decades, the standard drug regimen has been the MOPP program and its variants MVPP or ChlVPP. The search for less toxic chemotherapy in terms of decreased sterility and myelodysplasia-acute non-lymphocytic leukemia prompted the design of ABVD. Recent data from different countries indicate that adriamycin-based combinations as ABVD or MOPP alternating with ABVD appear very useful to improve treatment outcome compared to MOPP alone. The combination of chemotherapy and radiation has been utilized by many institutions in practically all stages of Hodgkin's disease. The intent is to optimize the cure rate and with the theory that less intensive therapy of both modalities may carry a lower risk of iatrogenic complications without compromising treatment outcome. In patients relapsing from curative radiotherapy, corabination chemotherapy such as ABVD or MOPP ABVD is recommended as the most effective salvage regimen, associated to further irradiation if technically feasible. In patients relapsing from primary chemotherapy, clinicians have first to take into consideration whether the duration of first complete remission is longer than 12 months. In this case, retreatment with the same drug regimen remains the treatment of choice. In patients with progressive lymphoma while on primary chemotherapy or showing remission duration lesser than 12 months, non-cross resistant chemotherapy or high dose therapy plus autologous bone marrow transplantation are indicated.

Original languageEnglish
Pages (from-to)69-73
Number of pages5
JournalBlood Reviews
Volume4
Issue number1
DOIs
Publication statusPublished - 1990

Fingerprint

Hodgkin Disease
Drug Therapy
Retreatment
Autologous Transplantation
Poisons
Combination Drug Therapy
Bone Marrow Transplantation
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Pharmaceutical Preparations
Doxorubicin
Infertility
Lymphoma
Radiotherapy
Therapeutics
Radiation

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Current issues in the management of advanced Hodgkin's disease. / Bonadonna, G.; Santoro, A.

In: Blood Reviews, Vol. 4, No. 1, 1990, p. 69-73.

Research output: Contribution to journalArticle

@article{995b1d478c2a42ec94c273dd3f746d09,
title = "Current issues in the management of advanced Hodgkin's disease",
abstract = "During the past two decades, the standard drug regimen has been the MOPP program and its variants MVPP or ChlVPP. The search for less toxic chemotherapy in terms of decreased sterility and myelodysplasia-acute non-lymphocytic leukemia prompted the design of ABVD. Recent data from different countries indicate that adriamycin-based combinations as ABVD or MOPP alternating with ABVD appear very useful to improve treatment outcome compared to MOPP alone. The combination of chemotherapy and radiation has been utilized by many institutions in practically all stages of Hodgkin's disease. The intent is to optimize the cure rate and with the theory that less intensive therapy of both modalities may carry a lower risk of iatrogenic complications without compromising treatment outcome. In patients relapsing from curative radiotherapy, corabination chemotherapy such as ABVD or MOPP ABVD is recommended as the most effective salvage regimen, associated to further irradiation if technically feasible. In patients relapsing from primary chemotherapy, clinicians have first to take into consideration whether the duration of first complete remission is longer than 12 months. In this case, retreatment with the same drug regimen remains the treatment of choice. In patients with progressive lymphoma while on primary chemotherapy or showing remission duration lesser than 12 months, non-cross resistant chemotherapy or high dose therapy plus autologous bone marrow transplantation are indicated.",
author = "G. Bonadonna and A. Santoro",
year = "1990",
doi = "10.1016/0268-960X(90)90017-M",
language = "English",
volume = "4",
pages = "69--73",
journal = "Blood Reviews",
issn = "0268-960X",
publisher = "Churchill Livingstone",
number = "1",

}

TY - JOUR

T1 - Current issues in the management of advanced Hodgkin's disease

AU - Bonadonna, G.

AU - Santoro, A.

PY - 1990

Y1 - 1990

N2 - During the past two decades, the standard drug regimen has been the MOPP program and its variants MVPP or ChlVPP. The search for less toxic chemotherapy in terms of decreased sterility and myelodysplasia-acute non-lymphocytic leukemia prompted the design of ABVD. Recent data from different countries indicate that adriamycin-based combinations as ABVD or MOPP alternating with ABVD appear very useful to improve treatment outcome compared to MOPP alone. The combination of chemotherapy and radiation has been utilized by many institutions in practically all stages of Hodgkin's disease. The intent is to optimize the cure rate and with the theory that less intensive therapy of both modalities may carry a lower risk of iatrogenic complications without compromising treatment outcome. In patients relapsing from curative radiotherapy, corabination chemotherapy such as ABVD or MOPP ABVD is recommended as the most effective salvage regimen, associated to further irradiation if technically feasible. In patients relapsing from primary chemotherapy, clinicians have first to take into consideration whether the duration of first complete remission is longer than 12 months. In this case, retreatment with the same drug regimen remains the treatment of choice. In patients with progressive lymphoma while on primary chemotherapy or showing remission duration lesser than 12 months, non-cross resistant chemotherapy or high dose therapy plus autologous bone marrow transplantation are indicated.

AB - During the past two decades, the standard drug regimen has been the MOPP program and its variants MVPP or ChlVPP. The search for less toxic chemotherapy in terms of decreased sterility and myelodysplasia-acute non-lymphocytic leukemia prompted the design of ABVD. Recent data from different countries indicate that adriamycin-based combinations as ABVD or MOPP alternating with ABVD appear very useful to improve treatment outcome compared to MOPP alone. The combination of chemotherapy and radiation has been utilized by many institutions in practically all stages of Hodgkin's disease. The intent is to optimize the cure rate and with the theory that less intensive therapy of both modalities may carry a lower risk of iatrogenic complications without compromising treatment outcome. In patients relapsing from curative radiotherapy, corabination chemotherapy such as ABVD or MOPP ABVD is recommended as the most effective salvage regimen, associated to further irradiation if technically feasible. In patients relapsing from primary chemotherapy, clinicians have first to take into consideration whether the duration of first complete remission is longer than 12 months. In this case, retreatment with the same drug regimen remains the treatment of choice. In patients with progressive lymphoma while on primary chemotherapy or showing remission duration lesser than 12 months, non-cross resistant chemotherapy or high dose therapy plus autologous bone marrow transplantation are indicated.

UR - http://www.scopus.com/inward/record.url?scp=0025344667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025344667&partnerID=8YFLogxK

U2 - 10.1016/0268-960X(90)90017-M

DO - 10.1016/0268-960X(90)90017-M

M3 - Article

C2 - 2182149

AN - SCOPUS:0025344667

VL - 4

SP - 69

EP - 73

JO - Blood Reviews

JF - Blood Reviews

SN - 0268-960X

IS - 1

ER -